Abstract
The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Current Neurovascular Research
Title: Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Volume: 8 Issue: 3
Author(s): Andrei Anghel, Georgel Taranu, Edward Seclaman, Andreea Rata, Liviu Tamas, Horatiu Moldovan, Sorin Ursoniu, Corina Samoila, Mihai Ionac and Aurel Popa-Wagner
Affiliation:
Keywords: Gene therapy, VEGF, HGF, critical limb ischemia, vascular endothelial, hepatocyte, ischemia, peripheral arterial, analgesics, narcotics, Leriche-Fontaine, PAOD, Therapeutic
Abstract: The present clinical trial analyzed the safety of gene therapy using plasmidial constructs expressing vascular endothelial and hepatocyte growth factors in patients with critical limb ischemia. The study included 43 patients: 29 in the treatment group and 14 allocated to the placebo group. The primary end points were the rate of major amputations and the clinical safety of the method. Secondary end points were improvement of pain at rest, walking ability and the ankle/brachial pressure index. The overall major amputation rate was 31.04% in the treatment group and 71.42% in the placebo group (p=0.029). Pain at rest was improved in 65% of patients in the gene therapy group and in 7% in the placebo group (p=0.0006). There were no significant adverse effects in the treatment group. Conclusion: Gene therapy with vascular endothelial and hepatocyte growth factors is therapeutically safe and reduces the rate of major amputations and relieves pain at rest in patients with critical limb ischemia.
Export Options
About this article
Cite this article as:
Anghel Andrei, Taranu Georgel, Seclaman Edward, Rata Andreea, Tamas Liviu, Moldovan Horatiu, Ursoniu Sorin, Samoila Corina, Ionac Mihai and Popa-Wagner Aurel, Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia, Current Neurovascular Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720211796558050
DOI https://dx.doi.org/10.2174/156720211796558050 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology Update on the Important New Drug Target in Cardiovascular Medicine – the Vascular Glycocalyx
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery 5-HT1A Receptor, an Old Target for New Therapeutic Agents
Current Topics in Medicinal Chemistry Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Vitamin D in Chronic Kidney Disease: New Potential for Intervention
Current Drug Targets Intranasal Fluorescent Nanocrystals for Longitudinal <i>In Vivo</i> Evaluation of Cerebral Microlesions
Pharmaceutical Nanotechnology Targeted Ultrasound Imaging of Cancer: An Emerging Technology on its Way to Clinics
Current Pharmaceutical Design Hemodynamic Regulation of Metallopeptidases within the Vasculature
Protein & Peptide Letters Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Targeting Platelet G-Protein Coupled Receptors (GPCRs): Looking Beyond Conventional GPCR Antagonism
Current Vascular Pharmacology Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Current Medicinal Chemistry Concerns and Hopes for Stem Cell Therapy in Cardiology: Focus on Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Post Traumatic Lesion absence of β-Dystroglycan-Immunopositivity in Brain Vessels Coincides with the Glial Reaction and the Immunoreactivity of Vascular Laminin
Current Neurovascular Research Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Therapeutic Value of Statins for Vascular Remodeling
Current Vascular Pharmacology Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews